GE HealthCare Secures FDA Clearance for Photon Counting CT, Eyes US Launch
GE HealthCare’s Photonova Spectra photon-counting CT system has received FDA clearance and is now entering US commercialization preparations. The PCCT platform uses deep silicon detectors for higher spectral and spatial resolution, promising improved tissue characterization across neurological, oncological, musculoskeletal, thoracic and cardiac imaging.
1. FDA Clearance and Commercialization Plans
Photonova Spectra has obtained FDA clearance, marking the first photon-counting CT system cleared for use in the US. GE HealthCare is initiating production scaling and regulatory compliance steps to support commercial deployments later this year.
2. Photon Counting Technology Advantages
Unlike conventional CT, Photonova Spectra directly counts individual x-ray photons and measures their energy using deep silicon detectors. This approach delivers higher spectral and spatial resolution, enabling superior tissue characterization in complex neurological, oncological, musculoskeletal, thoracic and cardiac studies.
3. Academic Collaborations for PCCT Research
GE HealthCare is collaborating with the University of Wisconsin–Madison on protocols to reduce noise and motion artifacts, and with Stanford University on image reconstruction methods and workflow optimization. These partnerships aim to validate clinical benefits and expand novel PCCT applications once deployed.
4. Next Steps and Market Outlook
With clearance secured, GE HealthCare will target early adopter sites for installation and training before broader rollout. The company expects the Photonova Spectra launch to support growth in advanced imaging and strengthen its competitive position in the CT market.